Lee AJP Supplemental Material.pdf

This study uncovers a novel role for metformin in reducing inflammatory and atherogenic monocytes by dampening extramedullary myelopoiesis, thereby delaying atherosclerosis development under normoglycemic conditions. We demonstrate that metformin suppresses hematopoietic stem and progenitor cell mobilization and reduces macrophage-driven inflammation, providing mechanistic evidence for its anti-atherosclerotic potential beyond diabetes management. These findings highlight new therapeutic opportunities for metformin in cardiovascular disease, extending its clinical utility to the prevention of atherosclerosis in non-diabetic individuals.